Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Feb 14;116(4):464-471.
doi: 10.1038/bjc.2016.436. Epub 2017 Jan 12.

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer

T Ioka  1 , Y Komatsu  2 , N Mizuno  3 , A Tsuji  4 , S Ohkawa  5 , M Tanaka  6 , H Iguchi  7 , A Ishiguro  8 , M Kitano  9 , T Satoh  10 , T Yamaguchi  11 , K Takeda  12 , M Kida  13 , K Eguchi  14 , T Ito  15 , M Munakata  16 , T Itoi  17 , J Furuse  18 , C Hamada  19 , Y Sakata  16
Affiliations
Clinical Trial

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer

T Ioka et al. Br J Cancer. .

Abstract

Background: We aimed to compare the efficacy and safety of irinotecan/S-1 (IRIS) therapy with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer.

Methods: Patients were treated with oral S-1 (80-120 mg for 14 days every 4 weeks) plus intravenous irinotecan (100 mg m-2 on days 1 and 15 every 4 weeks; IRIS group) or oral S-1 group (80-120 mg daily for 28 days every 6 weeks). The primary endpoint was progression-free survival (PFS).

Results: Of 137 patients enrolled, 127 were eligible for efficacy. The median PFS in the IRIS group and S-1 monotherapy group were 3.5 and 1.9 months, respectively (hazard ratio (HR)=0.77; 95% confidence interval (CI), 0.53-1.11; P=0.18), while the median overall survival (OS) were 6.8 and 5.8 months, respectively (HR=0.75; 95% CI, 0.51-1.09; P=0.13). Response rate was significantly higher in the IRIS group than in the S-1 monotherapy group (18.3% vs 6.0%, P=0.03). Grade 3 or higher neutropenia and anorexia occurred more frequently in the IRIS group.

Conclusions: There was a trend for better PFS and OS in the IRIS group that could be a treatment arm in the clinical trials for gemcitabine-refractory pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

Tatsuya Ioka has received research fund and honoraria including Speakers from Bureau from Taiho Pharmaceutical and Yakult Honsha. Tatsuya Ioka held an advisory role for Taiho Pharmace utical. Yoshito Komatsu has received research fund and honoraria from Yakult Honsha and Taiho Pharmaceutical. Nobumasa Mizuno, Haruo Iguchi, and Junji Furuse have received honoraria from Taiho Pharmaceutical and Yakult Honsha. Nobumasa Mizuno and Atsushi Ishiguro have received research fund from Taiho Pharmaceutical. Akihito Tsuji and Junji Furuse have received research fund from Taiho Pharmaceutical and Yakult Honsha. Taroh Satoh has received research fund from Yakult Honsha. Junji Furuse and Yuh Sakata held an advisory role for Taiho Pharmaceutical and Yakult Honsha. Chikuma Hamada held an advisory role for Yakult Honsha. All the remaining authors have declared no conflict of interest.

Figures

Figure 1
Figure 1
Trial profile. *Represents that patients can be included in more than one category.
Figure 2
Figure 2
Kaplan–Meier curves for progression-free survival assessed by RECIST (A) and overall survival (B). CI, confidence interval; HR, hazard ratio; IRIS, irinotecan plus S-1; OS=overall survival; PFS=progression-free survival.
Figure 3
Figure 3
Subgroup analyses of progression-free survival assessed by RECIST (A) and overall survival (B). CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; IRIS, irinotecan plus S-1.
See this image and copyright information in PMC

References

    1. Burris HA, Moore MI, Anderson J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15: 2403–2413. - PubMed
    1. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreas cancer. N Engl J Med 364: 1817–1825. - PubMed
    1. Gill S, Ko YJ, Cripps M, Beaudoin A, Dhesy-Thind SK, Zulfiqar M, Zalewski P, Do T, Cano PO, Lam W, Dowden SD, Grassin H, Stewart J, Moore MJ (2016) PANCREOX: a randomized Phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 34: 3914–3920. - PubMed
    1. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non–small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24: 2237–2244. - PubMed
    1. Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL, Baiget M (2008) Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 14: 1788–1796. - PubMed

Publication types

MeSH terms